DFP 10917

Drug Profile

DFP 10917

Alternative Names: DFP-10917

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics
  • Mechanism of Action Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 29 Sep 2015 DFP 10917 is still in phase I/II trials for Acute myeloid leukaemia and Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA
  • 01 Sep 2012 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top